Quick Answer
KalVista Pharmaceuticals, Inc. reported Total Revenue of $12.69 million for fiscal year 2020.
KalVista Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $12.69M -21.3% |
| Revenue (ASC 606) | — | — | — | — | — | $12.69M -21.3% |
| Net Income | -$183.44M -44.9% |
-$126.64M -36.3% |
-$92.91M -12.8% |
-$82.34M -78.1% |
-$46.24M -58.8% |
-$29.12M -39.9% |
| Diluted EPS | -$3.69 -7.3% |
-$3.44 -3.3% |
-$3.33 +0.9% |
-$3.36 -38.8% |
-$2.42 -47.6% |
-$1.64 |
| Total Assets | $250.77M +6.5% |
$235.40M +28.5% |
$183.20M -10.1% |
$203.88M -25.0% |
$272.01M +194.0% |
$92.53M -21.7% |
| Cash and Equivalents | $131.62M +314.0% |
$31.79M -43.5% |
$56.24M +83.0% |
$30.73M -39.3% |
$50.59M +220.4% |
$15.79M -50.7% |
| Stockholders Equity | $95.39M -53.8% |
$206.58M +28.3% |
$161.03M -13.0% |
$185.09M -28.0% |
$257.19M +207.1% |
$83.75M -13.4% |
| R&D Expense | $71.71M -16.8% |
$86.17M +7.3% |
$80.28M +14.4% |
$70.17M +70.0% |
$41.29M +2.7% |
$40.19M +14.8% |
| Operating Income | -$188.00M -33.9% |
-$140.44M -26.7% |
-$110.87M -14.8% |
-$96.61M -66.8% |
-$57.92M -42.9% |
-$40.53M -35.9% |
| Shares Outstanding | 49.76M +17.0% |
42.52M +24.4% |
34.17M +39.2% |
24.55M +0.5% |
24.42M +36.9% |
17.85M +3.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $13.69M | — | +860.2% |
| Revenue (ASC 606) | September 30, 2025 | $13.69M | — | +860.2% |
| Net Income | September 30, 2025 | -$49.48M | -26.6% | +17.7% |
| Diluted EPS | September 30, 2025 | -$0.92 | -9.5% | +17.9% |
| Total Assets | September 30, 2025 | $339.93M | — | +57.7% |
| Cash and Equivalents | September 30, 2025 | $243.50M | — | +95.9% |
| Stockholders Equity | September 30, 2025 | $17.00M | -88.6% | -58.3% |
| R&D Expense | September 30, 2025 | $11.99M | -35.8% | -20.9% |
| Operating Income | September 30, 2025 | -$46.05M | -5.9% | +22.0% |
| Shares Outstanding | September 30, 2025 | 50.54M | — | +0.4% |
- KalVista Pharmaceuticals, Inc. reported Total Revenue of $12.69 million for fiscal year 2020.
- KalVista Pharmaceuticals, Inc. showed a decrease of -21.3% in Total Revenue compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported Revenue (ASC 606) of $12.69 million for fiscal year 2020.
- KalVista Pharmaceuticals, Inc. showed a decrease of -21.3% in Revenue (ASC 606) compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported Net Income of -$183.44 million for fiscal year 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -44.9% in Net Income compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported Diluted EPS of $3.69 per share (loss) for fiscal year 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -7.3% in Diluted EPS compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported Total Assets of $250.77 million for fiscal year 2025.
- KalVista Pharmaceuticals, Inc. showed an increase of +6.5% in Total Assets compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported Cash and Equivalents of $131.62 million for fiscal year 2025.
- KalVista Pharmaceuticals, Inc. showed an increase of +314.0% in Cash and Equivalents compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported Stockholders Equity of $95.39 million for fiscal year 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -53.8% in Stockholders Equity compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported R&D Expense of $71.71 million for fiscal year 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -16.8% in R&D Expense compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported Operating Income of -$188.00 million for fiscal year 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -33.9% in Operating Income compared to the prior fiscal year.
- KalVista Pharmaceuticals, Inc. reported Shares Outstanding of 49.76 million shares for fiscal year 2025.
- KalVista Pharmaceuticals, Inc. showed an increase of +17.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: